OTIS vs. MRNA

Last updated Jun 13, 2026

OTIS (Otis Worldwide Corporation) and MRNA (Moderna, Inc.) are both stocks. OTIS operates in Specialty Industrial Machinery (Industrials), while MRNA operates in Biotechnology (Healthcare). Over the past 5 years, OTIS returned -0.99%/yr vs -25.59%/yr for MRNA. At a 0.19 correlation, their price movements are largely independent.

Performance

OTIS vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Otis Worldwide Corporation (OTIS) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, OTIS achieves a -18.14% return, which is significantly lower than MRNA's 69.24% return.

OTIS

• 1D: 0.88%
• 1M: -0.37%
• YTD: -18.14%
• 6M: -18.87%
• 1Y: -24.67%
• 3Y*: -5.09%
• 5Y*: -0.99%
• 10Y*: —

MRNA

• 1D: 0.54%
• 1M: 1.77%
• YTD: 69.24%
• 6M: 69.42%
• 1Y: 87.14%
• 3Y*: -26.94%
• 5Y*: -25.59%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

OTIS vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
OTIS Otis Worldwide Corporation	-18.14%	-3.99%	5.17%	16.04%	-8.76%	30.41%	70.57%
MRNA Moderna, Inc.	69.24%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	230.81%

Correlation

The correlation between OTIS and MRNA is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.19
Correlation (3Y) Calculated over the trailing 3-year period	0.21
Correlation (5Y) Calculated over the trailing 5-year period	0.23
Correlation (All Time) Calculated using the full available price history since Mar 19, 2020	0.19

Fundamentals

Market Cap OTIS : $27.56B MRNA : $19.71B
EPS OTIS : $3.77 MRNA : -$8.16
PS Ratio OTIS : 1.90 MRNA : 8.78
Total Revenue (TTM) OTIS : $14.65B MRNA : $2.23B
Gross Profit (TTM) OTIS : $4.45B MRNA : -$309.00M
EBITDA (TTM) OTIS : $2.44B MRNA : -$3.02B

Return for Risk

OTIS vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OTIS

OTIS Risk / Return Rank: 6
OTIS Sharpe Ratio Rank: 4
OTIS Sortino Ratio Rank: 8
OTIS Omega Ratio Rank: 7
OTIS Calmar Ratio Rank: 9
OTIS Martin Ratio Rank: 3

MRNA

MRNA Risk / Return Rank: 78
MRNA Sharpe Ratio Rank: 80
MRNA Sortino Ratio Rank: 79
MRNA Omega Ratio Rank: 75
MRNA Calmar Ratio Rank: 79
MRNA Martin Ratio Rank: 76

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

OTIS vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Otis Worldwide Corporation (OTIS) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	OTIS	MRNA	Difference
Sharpe ratio: Return per unit of total volatility	-1.09	1.28	-2.37
Sortino ratio: Return per unit of downside risk	-1.37	2.13	-3.49
Omega ratio: Gain probability vs. loss probability	0.81	1.24	-0.43
Calmar ratio: Return relative to maximum drawdown	-0.85	2.34	-3.19
Martin ratio: Return relative to average drawdown	-1.69	4.59	-6.28

OTIS vs. MRNA - Sharpe Ratio Comparison

The current OTIS Sharpe Ratio is -1.09, which is lower than the MRNA Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of OTIS and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

OTIS vs. MRNA - Drawdown Comparison

The maximum OTIS drawdown since its inception was -32.44%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for OTIS and MRNA.

Drawdown Indicators

	OTIS	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-32.44%	-95.38%	+62.94%
Max Drawdown (1Y) Largest decline over 1 year	-30.00%	-35.51%	+5.51%
Max Drawdown (3Y) Largest decline over 3 years	-32.44%	-86.58%	+54.14%
Max Drawdown (5Y) Largest decline over 5 years	-32.44%	-95.38%	+62.94%
Current Drawdown Current decline from peak	-31.07%	-89.70%	+58.63%
Average Drawdown Average peak-to-trough decline	-8.99%	-57.06%	+48.07%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.14%	18.06%	-2.92%

Volatility

OTIS vs. MRNA - Volatility Comparison

The current volatility for Otis Worldwide Corporation (OTIS) is 5.68%, while Moderna, Inc. (MRNA) has a volatility of 17.56%. This indicates that OTIS experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	OTIS	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.68%	17.56%	-11.88%
Volatility (6M) Calculated over the trailing 6-month period	16.38%	48.82%	-32.44%
Volatility (1Y) Calculated over the trailing 1-year period	23.57%	64.75%	-41.18%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	22.11%	66.49%	-44.38%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.85%	72.15%	-46.30%

Dividends

OTIS vs. MRNA - Dividend Comparison

OTIS's dividend yield for the trailing twelve months is around 2.40%, while MRNA has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020
MRNA Moderna, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
OTIS Otis Worldwide Corporation	2.40%	1.89%	1.63%	1.46%	1.42%	1.06%	0.89%

Financials

Frequently Asked Questions

Can I hold both OTIS and MRNA in my portfolio?

OTIS and MRNA have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, OTIS or MRNA?

MRNA has higher volatility (17.56%) compared to OTIS (5.68%). In terms of maximum drawdown, OTIS dropped -32.44% vs MRNA's -95.38%.

Which has better risk-adjusted returns?

MRNA currently has the higher Sharpe Ratio (1.28 vs -1.09), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.